Back to search

Article

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune liver disease

2023-07-18

Abstract excerpt

<h4>Background</h4> Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many malignancies in recent years. However, immune-related adverse events (irAE) are a frequent concern in clinical practice. The safety profile of ICI for the treatment of malignancies in patients diagnosed with autoimmune liver disease (AILD) remains unclear. Due to this uncertainty, these patients were excluded from ICI...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
683bbfc1-1d2d-5a6c-b6ec-8f704ac67391
DOI
10.1101/2023.07.17.23292183
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune liver diseaseDOI 10.1101/2023.07.17.23292183
Hepatic Failure Associated with Immune Checkpoint Inhibitors: A Real-world Study from the Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseSemantic proximity
Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsSemantic proximity
The clinical phenotypes of autoimmune hepatitis: A comprehensive review.Semantic proximity
Baseline risk factors associated with immune related adverse events and atezolizumabSemantic proximity
Recent advances in clinical practice: epidemiology of autoimmune liver diseases.Semantic proximity
The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsSemantic proximity
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint BlockadeSemantic proximity
Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors.Semantic proximity
The current status and future of PD-L1 in liver cancerSemantic proximity
Thyroid-related Adverse Events Caused by Immune Checkpoint Inhibitors Associated with Therapeutic Outcomes in Cancer Patients: a systematic review and meta-analysisSemantic proximity
Cutting edge issues in autoimmune hepatitis.Semantic proximity
Risk of Extrahepatic Malignancies in Autoimmune Hepatitis: A Propensity Score-Matched Retrospective Cohort StudySemantic proximity
Select a neighboring publication to make it the new centre.